Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's Disease.
Animals
Caspase 3
/ metabolism
Corpus Striatum
/ metabolism
Disease Models, Animal
Dopamine
/ metabolism
Dopaminergic Neurons
/ drug effects
Enzyme Activation
Genotype
Glutamic Acid
/ metabolism
Long-Term Synaptic Depression
Mice
Mice, Knockout
Neuronal Plasticity
/ drug effects
Parkinson Disease
/ etiology
Protein Kinases
/ genetics
PINK1
Parkinson’s disease
caspase-3
long-term depression
striatum
synaptic plasticity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Jul 2019
11 Jul 2019
Historique:
received:
24
06
2019
revised:
04
07
2019
accepted:
09
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
24
12
2019
Statut:
epublish
Résumé
Caspases are a family of conserved cysteine proteases that play key roles in multiple cellular processes, including programmed cell death and inflammation. Recent evidence shows that caspases are also involved in crucial non-apoptotic functions, such as dendrite development, axon pruning, and synaptic plasticity mechanisms underlying learning and memory processes. The activated form of caspase-3, which is known to trigger widespread damage and degeneration, can also modulate synaptic function in the adult brain. Thus, in the present study, we tested the hypothesis that caspase-3 modulates synaptic plasticity at corticostriatal synapses in the phosphatase and tensin homolog (PTEN) induced kinase 1 (PINK1) mouse model of Parkinson's disease (PD). Loss of PINK1 has been previously associated with an impairment of corticostriatal long-term depression (LTD), rescued by amphetamine-induced dopamine release. Here, we show that caspase-3 activity, measured after LTD induction, is significantly decreased in the PINK1 knockout model compared with wild-type mice. Accordingly, pretreatment of striatal slices with the caspase-3 activator α-(Trichloromethyl)-4-pyridineethanol (PETCM) rescues a physiological LTD in PINK1 knockout mice. Furthermore, the inhibition of caspase-3 prevents the amphetamine-induced rescue of LTD in the same model. Our data support a hormesis-based double role of caspase-3; when massively activated, it induces apoptosis, while at lower level of activation, it modulates physiological phenomena, like the expression of corticostriatal LTD. Exploring the non-apoptotic activation of caspase-3 may contribute to clarify the mechanisms involved in synaptic failure in PD, as well as in view of new potential pharmacological targets.
Identifiants
pubmed: 31336695
pii: ijms20143407
doi: 10.3390/ijms20143407
pmc: PMC6678522
pii:
doi:
Substances chimiques
Glutamic Acid
3KX376GY7L
Protein Kinases
EC 2.7.-
PTEN-induced putative kinase
EC 2.7.11.1
Caspase 3
EC 3.4.22.-
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Neuropharmacology. 1999 Jul;38(7):943-54
pubmed: 10428413
J Neurosci Res. 1999 Oct 1;58(1):167-90
pubmed: 10491581
Brain Res. 2000 Apr 10;861(2):296-304
pubmed: 10760491
J Neurosci. 2000 May 15;20(10):3641-9
pubmed: 10804206
Neuroreport. 2000 Aug 21;11(12):2811-6
pubmed: 10976968
Nature. 2000 Oct 12;407(6805):770-6
pubmed: 11048727
J Cell Biol. 2000 Oct 30;151(3):483-94
pubmed: 11062251
J Neurosci. 2002 Mar 1;22(5):1608-17
pubmed: 11880491
Neuromolecular Med. 2002;1(1):69-79
pubmed: 12025817
Neuroscience. 2002;114(1):217-27
pubmed: 12207967
Neuromolecular Med. 2002;2(2):197-214
pubmed: 12428811
Neuron. 2003 Mar 27;37(6):939-52
pubmed: 12670423
J Biol Chem. 2003 Oct 31;278(44):43628-35
pubmed: 12930822
Science. 2004 May 21;304(5674):1158-60
pubmed: 15087508
Neuron. 2005 Feb 17;45(4):489-96
pubmed: 15721235
Annu Rev Neurosci. 2005;28:127-56
pubmed: 16022592
Eur J Neurosci. 2006 Jan;23(1):129-40
pubmed: 16420423
Apoptosis. 2006 Feb;11(2):197-207
pubmed: 16502258
Brain Res. 2006 May 17;1089(1):44-54
pubmed: 16638611
Neuron. 2006 Aug 3;51(3):283-90
pubmed: 16880123
Nat Neurosci. 2006 Oct;9(10):1234-6
pubmed: 16980964
J Neurosci. 2006 Oct 4;26(40):10270-80
pubmed: 17021182
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11441-6
pubmed: 17563363
J Neurophysiol. 2007 Dec;98(6):3221-9
pubmed: 17942621
J Neurosci. 2007 Dec 5;27(49):13520-31
pubmed: 18057210
Dialogues Clin Neurosci. 2007;9(4):389-97
pubmed: 18286799
J Neurochem. 2009 Jul;110(2):613-21
pubmed: 19457102
Brain. 2009 Sep;132(Pt 9):2336-49
pubmed: 19641103
Oncogene. 2008 Dec;27 Suppl 1:S53-70
pubmed: 19641507
J Neurobiol. 1990 Oct;21(7):1072-84
pubmed: 1979610
Cell Death Differ. 2010 Jul;17(7):1104-14
pubmed: 19960023
EMBO Mol Med. 2009 May;1(2):99-111
pubmed: 20049710
Cell. 2010 May 28;141(5):859-71
pubmed: 20510932
Neuron. 2011 May 26;70(4):758-72
pubmed: 21609830
Neuroscience. 2012 Jun 1;211:126-35
pubmed: 21839811
Neurosci Bull. 2012 Feb;28(1):14-24
pubmed: 22233886
Mol Brain. 2012 May 14;5:15
pubmed: 22583788
J Neurosci. 2012 Aug 29;32(35):11991-2004
pubmed: 22933784
J Neurochem. 2013 May;125(3):373-85
pubmed: 23406303
Cell Death Differ. 2013 Jul;20(7):920-30
pubmed: 23519076
Oxid Med Cell Longev. 2013;2013:601587
pubmed: 23533695
Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a008656
pubmed: 23545416
J Neurosci. 2013 May 22;33(21):8923-5
pubmed: 23699503
Cold Spring Harb Perspect Biol. 2013 Jun 01;5(6):null
pubmed: 23732469
Mov Disord. 2014 Jan;29(1):41-53
pubmed: 24167038
Neurobiol Dis. 2014 May;65:124-32
pubmed: 24503369
Dev Cell. 2014 Mar 31;28(6):604-6
pubmed: 24697895
Neuron. 2014 Jul 16;83(2):404-416
pubmed: 25033183
Cell Death Differ. 2015 Apr;22(4):526-39
pubmed: 25526085
PLoS One. 2015 Mar 06;10(3):e0119809
pubmed: 25748204
Neurobiol Dis. 2016 Jul;91:21-36
pubmed: 26916954
Front Neurol. 2018 May 04;9:295
pubmed: 29780350
Brain Res. 1993 Nov 5;627(1):1-8
pubmed: 7904885
Nature. 1996 Nov 28;384(6607):368-72
pubmed: 8934524
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2665-70
pubmed: 9122253
Brain Res. 1998 Feb 2;783(1):133-42
pubmed: 9479062